These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 31991225)

  • 41. Pan-cancer landscape of
    Kelly AD; Murugesan K; Kuang Z; Montesion M; Ross JS; Albacker LA; Huang RSP; Lin DI; Demirci U; Creeden J
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.
    Domblides C; Antoine M; Hamard C; Rabbe N; Rodenas A; Vieira T; Crequit P; Cadranel J; Lavolé A; Wislez M
    AIDS; 2018 Feb; 32(4):461-468. PubMed ID: 29194117
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
    Yang Z; Xu J; Li R; Gao Y; He J
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3055-3065. PubMed ID: 31522278
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
    Shi WJ; Zhao W
    Chin Med J (Engl); 2020 Oct; 133(20):2466-2475. PubMed ID: 32960841
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.
    Lagos GG; Izar B; Rizvi NA
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32315237
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
    Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
    Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
    Shibaki R; Murakami S; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Kusumoto M; Yamamoto N; Ohe Y
    Med Oncol; 2019 Apr; 36(6):49. PubMed ID: 31030326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R
    Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status.
    Shalata W; Maimon Rabinovich N; Agbarya A; Yakobson A; Dudnik Y; Abu Jama A; Cohen AY; Shalata S; Abu Hamed A; Ilan Ber T; Machluf O; Shoham Levin G; Meirovitz A
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma.
    Burcher KM; Lantz JW; Gavrila E; Abreu A; Burcher JT; Faucheux AT; Xie A; Jackson C; Song AH; Hughes RT; Lycan T; Bunch PM; Furdui CM; Topaloglu U; D'Agostino RB; Zhang W; Porosnicu M
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. γH2AX, a DNA Double-Strand Break Marker, Correlates with PD-L1 Expression in Smoking-Related Lung Adenocarcinoma.
    Sakurai E; Ishizawa H; Kiriyama Y; Michiba A; Hoshikawa Y; Tsukamoto T
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer.
    Greally M; Chou JF; Chatila WK; Margolis M; Capanu M; Hechtman JF; Tuvy Y; Kundra R; Daian F; Ladanyi M; Kelsen DP; Ilson DH; Berger MF; Tang LH; Solit DB; Diaz LA; Schultz N; Janjigian YY; Ku GY
    Clin Cancer Res; 2019 Oct; 25(20):6160-6169. PubMed ID: 31337644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical Observation of Immunotherapy Efficacy and Adverse Effects 
in Chinese Patients with Lung Squamous Cell Carcinoma].
    Yu J; Wu X; Ma J; Chen X; Li L
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):546-554. PubMed ID: 35899455
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
    Tseng JS; Yang TY; Wu CY; Ku WH; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Chang GC
    J Immunother; 2018; 41(6):292-299. PubMed ID: 29683890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune Oncology Biomarkers in Lung Cancer: an Overview.
    Travert C; Barlesi F; Greillier L; Tomasini P
    Curr Oncol Rep; 2020 Aug; 22(11):107. PubMed ID: 32803433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
    Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
    BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.